

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 September 2023 (14.09.2023)



(10) International Publication Number
WO 2023/170715 A1

(51) International Patent Classification:

A61K 31/00 (2006.01) C07C 259/06 (2006.01)
A61P 35/00 (2006.01) C07C 239/08 (2006.01)
C07D 487/04 (2006.01) C07C 231/12 (2006.01)

(21) International Application Number:

PCT/IN2023/050233

(22) International Filing Date:

10 March 2023 (10.03.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

202241013165 10 March 2022 (10.03.2022) IN
63/368,342 13 July 2022 (13.07.2022) US
202241057045 04 October 2022 (04.10.2022) IN

(71) Applicant: JUBILANT EPICORE LLC [US/US]; 1430
US Highway 206, Suite 110, Bedminster, New Jersey 07921
(US).

(72) Inventor; and

(71) Applicant: SRIDHARAN, Rajagopal [IN/IN]; Jubilant
Therapeutics India Ltd, # 96, Industrial Suburb, 2nd
Stage, Industrial Area, Yeshwanthpur, Karnataka, Banga-
lore 560022 (IN).

(72) Inventors: SADHU, Naveen; Jubilant Therapeutics In-
dia Ltd, # 96, Industrial Suburb, 2nd Stage, Industrial
Area, Yeshwanthpur, Karnataka, Bangalore 560022 (IN).
SIVANANDHAN, Dhanalakshmi; Jubilant Therapeutics
India Ltd, # 96, Industrial Suburb, 2nd Stage, Indus-
trial Area, Yeshwanthpur, Karnataka, Bangalore 560022
(IN). RASTELLI, Luca; 1430 US Highway 206, Suite
110, Bedminster, New Jersey 07921 (US). GAJENDRAN,
Chandru; Jubilant Therapeutics India Ltd, # 96, Indus-
trial Suburb, 2nd Stage, Industrial Area, Yeshwanthpur, Kar-
nataka, Bangalore 560022 (IN).

(74) Agent: LAKSHMIKUMARAN, Malathi et al.; B6/10,
Safdarjung Enclave, New Delhi 110029 (IN).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,

LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(54) Title: DUAL LSD1/HDAC INHIBITORS

(57) Abstract: The present disclosure provides a compound of Formula (I), its analogs, tautomeric forms, stereoisomers, enantiomers, diastereomers and pharmaceutically acceptable salts thereof. The present disclosure also provides a process for preparing the compounds of Formula (I), its analogs, tautomeric forms, stereoisomers, enantiomers, diastereomers and pharmaceutically acceptable salts thereof. The compounds of Formula (I) modulates MYC or coREST, in a subject in need thereof. The compounds of Formula (I) inhibits HDAC enzymes or LSD1 enzymes, or both HDAC enzymes and LSD1 enzymes. The compound of Formula (I) is an epigenetic modulating agent with a novel mechanism of action that target MYC amplification in multiple neuroendocrine tumors types.

WO 2023/170715 A1